Criminalizing the legal advisors

refco122007.jpgRegular readers of this blog know that the federal government’s criminalization of business since Enron has been steadily encroaching on professionals who provide advice to business interests. First, it was Arthur Andersen, then the Merrill Lynch bankers in the Nigerian Barge case, and then KPMG.
Now, Nathan Koppel of the WSJ Law Blog reports that the Department of Justice has thrown down the criminal gauntlet on legal advisors by indicting former Refco, Inc outside counsel, Joseph P. Collins, the former head of Mayer, Brown & Platt’s derivatives section. A copy of the indictment is here and my previous posts on the Refco case are here.
The indictment crosses the Rubicon in terms of the govenment’s willingness to prosecute an outside lawyer for merely advising a client in regard to structuring transactions that are not intrinsically illegal, but it nevertheless raises more questions than it answers. As is typical of most business prosecutions over the past several years that criminalize questionable business judgment rather than clear white collar criminal acts such as embezzlement, the indictment of Collins is a jumble of conclusory allegations of fraud without any specific allegations of Collins’ fraudulent conduct.
Although inartfully drafted, the government’s indictment essentially alleges that Collins assisted former Refco CEO and controlling shareholder Phillip Bennett in using Refco’s credit to reduce indebtedness to Refco of an affiliate controlled by Bennett. That’s not a crime, but the government alleges that Collins committed a crime by aiding Bennett in misleading Refco auditors and investors in not telling them about the use of Refco’s credit to reduce the affiliate’s debt to Refco. In addition, the government alleges that Collins aided Bennett in covering up from investors the dilution of Bennett’s ownership interest in Refco to BAWAG, which is characterized as “a longtime Refco customer.” Again, the government hinges its criminal case against Collins on the alleged non-disclosure of that dilution.
What’s curious about all of this is that numerous lawyers, accountants and investment bankers scrutinized and presumably profited from Refco over the past several years in connection with various investments in the firm, including its well-publicized public offering that valued the company at $4 billion five months before it disintegrated into a bankruptcy case. Not only did none of these professionals uncover the alleged fraud, but none of them other than Collins has been targeted as a criminal. Moreover, as this earlier post asks, if Bennett and Collins were orchestrating a massive fraud at Refco, then why on earth did they take it public where discovery of the fraud would likely lead to far more draconian consequences than if Refco had remained private?
Oh well, I suppose that question will be sorted out eventually. An ominous sign for both Bennett and Collins is that former Refco Capital Markets vice-president, Santo C. Maggio, pled guilty yesterday in New York to two counts of securities fraud, one count of conspiracy and one count of wire fraud under a cooperation agreement with prosecutors. In the meantime, it looks as if Collins and Bennett are not in lockstep with regard to defending their criminal cases. The initial public comments of Collins’ attorney suggest that Collins will assert that he had been duped by Refco’s fraud. Although that position can’t be pleasing to the Bennett defense, it is certainly understandable from Collins and Mayer Brown’s standpoint. It appears that Mayer Brown is underwriting Collins’ defense and probably will continue to do so as long as Collins is taking the position that any failure of his legal counsel was the result of being duped or, at worst, negligence.
Maintaining that position would appear to be extremely important to Mayer Brown, which has had been having its own business problems over the past year or so (see here, here and here). If a jury finds that Collins was engaged in criminal fraud with regard to Refco, then such a finding would likely constitute grounds for any insurer or reinsurer of Mayer Brown to deny coverage for damage claims arising from Refco-related civil litigation against the firm, as well as any legal fees generated in the defense of such litigation. In that turns out to be the case, Mayer Brown’s resulting business problems may make the ones that the firm has been dealing with over the past year look like a piece of cake in comparison.
As always, Larry Ribstein and Peter Henning have insightful thoughts on various implications of the Collins indictment.

Mitchell Report redux

Mitchell Report cover.jpgFollowing on my post on the Mitchell Report, the following are a few interesting observations from the past several days:

Art DeVany agrees with me that MLB didn’t get it’s money’s worth and provides a rather interesting and simple test to evaluate whether a player was likely to have used steroids;
Malcolm Gladwell asks “So what, exactly, is wrong with an athlete–someone who makes a living with their body–taking medication to speed their recovery from injury?”
The New York Times Murray Chass picks up on one of the observations from my post — that is, there is not much original work product in the Mitchell Report.
Former Florida Marlins and Cincinnati Reds trainer Larry Starr, who was a trainer in the big leagues for 30 years, describes how MLB management and the MLB Players’ Association soft-pedaled the PED problem even after being advised in 1988 that use of PED’s was becoming commonplace among players.

Finally, Richard Landau and Louis H. Philipson, who are both Professors of Medicine at the University of Chicago Medical School, wrote the following letter to the Wall Street Journal explaining why the risks of taking human growth hormone in an effort to improve athletic performance and endurance, or recover from a non-live threatening injury, is a quintessential example of taking a flyer with too much downside risk:

While some stories noted the many negative effects of androgenic steroids, we have not seen any explanation as to why taking “natural” human growth hormone is also a really bad idea. While growth hormone is necessary for children in particular, athletes are tempted to take growth hormone without a demonstrated positive result on performance. They should note what happens in the disease called acromegaly, a condition of too much growth hormone. In this disease, excess growth hormone causes growth of hands, lips, tongue, feet, nose, chin, forehead and liver. In short, most tissues and organs in the body will enlarge, including the heart, sometimes to the point of heart failure. Diabetes, decreased interest and ability in sex, fatigue, excessive sweating, and disordered sleep are also part of this syndrome.
The only important FDA-approved indications for giving growth hormone are failure to grow due to lack of growth hormone and the HIV-associated wasting syndrome. Despite the relative rarity of these problems, there are nine formulations of growth hormone on the market today, and all list diabetes, leukemia, muscle aches and pain, headache, weakness, stiffness and swelling of male breasts as potential side effects, as well as insomnia, nausea, hypothyroidism and increased blood fats. Also mentioned are pancreatitis and fatigue. Every manufacturer recommends periodic safety monitoring of blood sugar, thyroid blood tests, skin and heart exams. We could easily name quite a few drugs that have been withdrawn from the market with less potential for harm than growth hormone.
Not a single clinical trial has effectively demonstrated that the metabolic effects of growth hormone, even including a temporary increase in lean body mass, have resulted in improved performance. The view of some athletes that a few injections of the hormone might have beneficial effects on sore arms has never been rigorously tested, but is very unlikely to be effective. The risks clearly outweigh the benefits. Our young athletes need to be warned that large muscles are not good muscles, and that these problems are not rare “side effects” but the natural consequence of excess growth hormone, a hormone that affects almost every tissue, not just muscles — and usually not for the better. Taking any form of growth hormone in the hope of improved athletic performance is misinformed at best, and any mention of this practice should explain why.

What is Reyes Being Sentenced for Again?

The illusory nature of the financial damages attributed to former Brocade CEO Greg Reyes’ backdating of stock options, the W$J’s Holman Jenkins — who has been the most lucid mainstream media voice condemning the witch hunt mentality that permeated the criminal prosecutions involving backdated stock options — pens this column on the Reyes sentencing, in which he concludes:

Punishment should fit the crime; dozens of executives have lost jobs over backdating; a few have been asked to disgorge money and sign regulatory settlements that don’t require acknowledgment of wrongdoing. Even the trial lawyers have been unable to make a meal out of this scandal, thanks to an absence of demonstrable shareholder harm.

The great flaw in the Reyes prosecution, which was the first of its kind, was the prosecution’s attempt to fulfill the media image of backdating, rather than focusing on the venial offense it was. The government has suggested Mr. Reyes should face 10-20 years. Judge Charles Breyer, in a recommendation recently unsealed, proposed 15-21 months. Some law bloggers think it not impossible Mr. Reyes will receive a suspended sentence.

Let’s hope so. Because unless we plan to send Steve Jobs and a hundred other executives to jail for backdating, it would be grossly disproportionate to inflict jail on Mr. Reyes.

Read the entire column. By the way, the Reyes sentencing has been postponed indefinitely.